Profile Response Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

Molecular Profile ARID1A mutant
Therapy Bevacizumab + Everolimus
Indication/Tumor Type renal cell carcinoma
Response Type predicted - sensitive


  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")


  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
ARID1A mutant renal cell carcinoma predicted - sensitive Bevacizumab + Everolimus Case Reports/Case Series Actionable In a Phase II trial, 100% (7/7) of patients with papillary renal cell carcinoma (n=3) or unclassified renal cell carcinoma with papillary features (n=4) harboring ARID1A mutations achieved the primary endpoint of 6-month progression-free survival when treated with the combination of Afinitor (everolimus) and Avastin (bevacizumab) (PMID: 32975815; NCT01399918). 32975815
PubMed Id Reference Title Details
(32975815) Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial. Full reference...